July 2020

When delegates returned from the 38th annual JP Morgan Healthcare Conference in San Diego in mid-January this year, few can have imagined just how fast, and how dramatically, the biotech industry was about to change. Fewer than 10,000 cases of COVID-19 had been reported to the WHO by the end of that month, and few, other than infectious disease specialists, were taking very much notice of those reports.